FundedIQ
Biotechnology

Brenus Pharma: Funding, Investors & Team (Sep 2026)

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of activating the patient's immune system to combat cancer and reduce resistance to treatment.

www.brenus-pharma.com LinkedIn Issoire, France 11-50 employees Founded 2014
Biotechnology Pharmaceutical B2B
Total raised
$37.6M
Rounds
2
Latest
Series A
Jul 2026

Brenus Pharma has raised $37.6M across 2 funding rounds on record, the most recent a Series A of $12.6M announced in Jul 2026.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Brenus Pharma Company Profile and Key Stats

Total funding raised
$37.6M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Series A
$12.6M in Jul 2026
Employees
11-50
reported band
Founded
2014
Headquarters
Issoire, France
Investors on record
16
5 named below

Latest funding round on record: Jul 2026.

Brenus Pharma Funding Rounds

Date
Round
Amount
Series A
$12.6M
Series A
$25.0M

Brenus Pharma raised $25.0M in a Series A announced in Sep 2024.

1.8 years later, a Series A of $12.6M was announced in Jul 2026.

Brenus Pharma Investors

Bpifrance Crédit Agricole UI Investissement Eurostars Noshaq

16 investors are recorded in total; the 5 named above are those the record identifies.

Brenus Pharma Founders and Leadership Team

Name
Role
Contact
Paul Bravetti
Chief Executive Officer
Locked
Benoit Pinteur
Founder
Locked

Contact details for the Brenus Pharma team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.

Start 14-day free trial →

Brenus Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,183
$8.0M
1,708
$6.9M
8,422
$15M

Brenus Pharma's latest round of $12.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Brenus Pharma in Biotechnology and Issoire

Companies Similar to Brenus Pharma

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…

Undisclosed round $6.9M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

CTIBiotech is a biotechnology firm that focuses on cancer research, stem cells, governmental consulting, and…

Undisclosed round $1.5M

Brenus Pharma Funding FAQs

What does Brenus Pharma do?

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of activating the patient's immune system to combat cancer and reduce resistance to treatment.

How much funding has Brenus Pharma raised?

Brenus Pharma has raised $37.6M across 2 rounds on record. The most recent is a Series A of $12.6M announced in Jul 2026.

When did Brenus Pharma last raise funding?

Brenus Pharma's most recent funding round on record is a Series A of $12.6M, announced in Jul 2026.

Who has invested in Brenus Pharma?

Investors on record for Brenus Pharma include Bpifrance, Crédit Agricole, UI Investissement, Eurostars, Noshaq. FundedIQ records 16 investors in total.

Who founded Brenus Pharma?

FundedIQ lists Benoit Pinteur (Founder) at Brenus Pharma.

Who is the CEO of Brenus Pharma?

Paul Bravetti is listed as Chief Executive Officer at Brenus Pharma.

Where is Brenus Pharma headquartered?

Brenus Pharma is based in Issoire, Auvergne, France.

How many employees does Brenus Pharma have?

Brenus Pharma is in the 11-50 employee band.

When was Brenus Pharma founded?

Brenus Pharma was founded in 2014.

How does Brenus Pharma's funding compare to other Biotechnology startups?

Brenus Pharma's latest round of $12.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's Brenus Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Brenus Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.